Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies

Affiliations

¹ Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany.
² Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
³ Vita-Salute San Raffaele University and Division of Transplantation, Immunology and Transplantation Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁴ Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
⁵ Lymphoma Coalition Europe, Madrid, Spain.
⁶ CHU de Rennes, Université de Rennes, INSERM U1236, Rennes, France.
⁷ Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁸ IRCCS, Bambino Gesù Children's Hospital, Sapienza University of Rome, Rome, Italy.
⁹ Myeloma UK, Edinburgh, UK.
¹⁰ UCL Institute of Immunity and TransplantationRoyal Free Hospital, London, UK.
¹¹ Department of Haematology, University Hospital Galway and National University of Ireland, Galway.
¹² Sant Pau Biomedical Research Institute and Jose Carreras Leukemia Research Institute, Barcelona, Spain.
¹³ Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁴ Amsterdam UMC, VU Medical Center, Amsterdam, the Netherlands.

Editorial

Hermann Einsele et al. Hemasphere. 2020.

. 2020 Jun 29;4(4):e423.

doi: 10.1097/HS9.0000000000000423. eCollection 2020 Aug.

¹ Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany.
² Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
³ Vita-Salute San Raffaele University and Division of Transplantation, Immunology and Transplantation Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁴ Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
⁵ Lymphoma Coalition Europe, Madrid, Spain.
⁶ CHU de Rennes, Université de Rennes, INSERM U1236, Rennes, France.
⁷ Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁸ IRCCS, Bambino Gesù Children's Hospital, Sapienza University of Rome, Rome, Italy.
⁹ Myeloma UK, Edinburgh, UK.
¹⁰ UCL Institute of Immunity and TransplantationRoyal Free Hospital, London, UK.
¹¹ Department of Haematology, University Hospital Galway and National University of Ireland, Galway.
¹² Sant Pau Biomedical Research Institute and Jose Carreras Leukemia Research Institute, Barcelona, Spain.
¹³ Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁴ Amsterdam UMC, VU Medical Center, Amsterdam, the Netherlands.

No abstract available

Conflict of interest statement

The authors have indicated they have no potential conflicts of interest to disclose.

1. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361–370. - PMC - PubMed
1. Hutchings CJ, Koglin M, Olson WC, et al. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017;16:787–810. - PubMed
1. Kennedy PJ, Oliveira C, Granja PL, et al. Monoclonal antibodies: technologies for early discovery and engineering. Crit Rev Biotechnol. 2018;38:394–408. - PubMed
1. van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270:95–112. - PMC - PubMed
1. Salles G, Barrett M, Foà R, et al. Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232–2273. - PMC - PubMed